By Isnaini Azizah 
Eli Lilly announced on Thursday that its highly anticipated next-generation obesity treatment, retatrutide, has successfully cleared its first late-stage clinical trial involving patients with Type 2 diabetes, marking a significant advancement in the pharmaceutical giant’s efforts to dominate the metabolic health market. The study demonstrated that the experimental drug not only helped patients achieve superior control over their blood sugar levels but also produced weight loss results that are historically difficult to attain for those living with diabetes. As the global healthcare landscape shifts toward more potent, multi-hormonal therapies, the success of this Phase 3 trial positions Eli Lilly to potentially disrupt its own market-leading portfolio, including the blockbuster drug Zepbound.
According to the data released by the Indianapolis-based company, retatrutide met its primary endpoint by significantly lowering hemoglobin A1c—a critical long-term measure of blood sugar levels—by an average of 1.7% to 2% across various dosage strengths over a 40-week period. These results were compared against a placebo group, highlighting the drug’s efficacy in a patient population that began the trial with A1c levels ranging from 7% to 9.5%. Notably, these participants were not taking other diabetes medications at the start of the study, providing a clear window into retatrutide’s standalone therapeutic potential.
Beyond glycemic control, the drug’s secondary objectives revealed even more striking outcomes regarding body composition. Patients receiving the highest dose of retatrutide lost an average of 16.8% of their body weight, equivalent to approximately 36.6 pounds, over the 40-week duration. This figure represents the "on-treatment" analysis, focusing on participants who adhered to the medication protocol. When looking at the "intent-to-treat" population—which includes those who may have discontinued the drug for any reason—the weight loss remained a robust 15.3%.
For clinical experts and researchers, these numbers are particularly noteworthy because patients with Type 2 diabetes have traditionally faced greater metabolic hurdles when attempting to lose weight compared to those without the condition. The metabolic dysfunction inherent in diabetes often makes the body more resistant to the weight-loss effects of standard GLP-1 therapies. Ken Custer, President of Lilly Cardiometabolic Health, emphasized this point in a recent interview, noting that the company is "very excited" to see a drug deliver such competitive drops in blood sugar alongside weight loss percentages that rival those seen in non-diabetic populations.
The science behind retatrutide is what sets it apart from current market leaders like Novo Nordisk’s Wegovy or Lilly’s own Zepbound. Retatrutide has been colloquially dubbed the "triple G" drug because of its unique mechanism of action. While Wegovy (semaglutide) targets only the glucagon-like peptide-1 (GLP-1) receptor, and Zepbound (tirzepatide) targets both GLP-1 and the glucose-dependent insulinotropic polypeptide (GIP), retatrutide adds a third layer: the glucagon receptor. By mimicking these three hunger-regulating hormones simultaneously, retatrutide aims to provide a more comprehensive metabolic intervention.
The inclusion of glucagon is a strategic masterstroke in drug design. While GLP-1 and GIP primarily focus on insulin secretion, slowing gastric emptying, and signaling satiety to the brain, glucagon plays a pivotal role in increasing energy expenditure and affecting lipid metabolism in the liver. By stimulating all three pathways, retatrutide appears to offer a more potent suppression of appetite while simultaneously revving up the body’s internal furnace, leading to the dramatic weight loss observed in the latest data.
Despite the excitement surrounding retatrutide, Eli Lilly is navigating a complex internal and external competitive environment. Interestingly, the A1c reduction observed with retatrutide—while impressive—did not surpass the highest benchmarks set by Zepbound. In previous SURPASS clinical trials, the highest dose of Zepbound lowered A1c by more than 2% over 40 weeks. However, Custer pointed out that retatrutide’s performance remains "very, very strong," particularly when compared to any diabetes medication that does not utilize this specific multi-hormonal approach.
The real differentiator remains the weight loss. In the SURPASS-2 trial, the highest dose of Zepbound led to a 13.1% weight reduction at 40 weeks, and in SURPASS-1, that figure was 11%. Retatrutide’s 16.8% achievement in a similar timeframe suggests it could become the gold standard for patients whose primary clinical goal is maximum weight reduction alongside diabetes management. Custer suggested that the future of metabolic medicine will rely on "individualized tailoring," where physicians choose between Zepbound, retatrutide, or the company’s upcoming oral pill, orforglipron, based on the specific needs and goals of the patient.
Safety remains a paramount concern for these high-potency injectables. The trial results indicated that retatrutide’s safety profile is largely consistent with existing incretin-based therapies. The most common adverse events were gastrointestinal in nature. Specifically, 26.5% of patients on the highest dose reported nausea, 22.8% experienced diarrhea, and 17.6% reported vomiting. While these side effects are common for this class of drugs, Lilly was encouraged by the relatively low discontinuation rate. Only about 5% of participants stopped taking the drug due to side effects, a figure that suggests the titration schedule and tolerability of the "triple G" approach are manageable for the vast majority of patients. One minor observation in the study was the occurrence of dysesthesia—an unpleasant, abnormal sense of touch—though this was reported at low rates.
The pharmaceutical industry is currently in the midst of what many analysts call the "Obesity Wars," a high-stakes race to capture a market expected to exceed $100 billion by the end of the decade. As Lilly moves retatrutide toward the finish line, its primary rival, Novo Nordisk, is not standing still. In March 2025, Novo Nordisk signaled its intent to challenge Lilly’s triple-agonist dominance by committing up to $2 billion to acquire the rights to an experimental triple-hormone drug from the Chinese firm United Laboratories International. While Novo’s candidate is significantly further behind in the developmental pipeline—trailing retatrutide by several years—the move underscores the industry’s consensus that triple-agonist therapies represent the next frontier of metabolic care.
Lilly’s strategic roadmap for retatrutide is aggressive. While the company has not yet filed for regulatory approval for either obesity or diabetes, it is currently conducting an expansive clinical program. Findings from seven additional Phase 3 trials are expected to be reported by the end of this year. These trials will likely explore retatrutide’s impact on a variety of comorbidities, including obstructive sleep apnea, non-alcoholic steatohepatitis (NASH), and chronic kidney disease, mirroring the successful expansion strategy Lilly employed for tirzepatide.
The broader implications of these findings extend beyond corporate balance sheets. For the millions of people living with Type 2 diabetes, the arrival of retatrutide could signal a shift in how the disease is managed. Traditionally, diabetes treatment focused heavily on glucose control, often at the expense of weight (as some older medications like insulin or sulfonylureas can actually cause weight gain). The new generation of "triple G" drugs flips this script, treating obesity as the root cause of metabolic dysfunction rather than a secondary symptom.
As the healthcare industry awaits the remaining Phase 3 data, the focus will turn to the logistical and economic challenges of these therapies. Issues such as manufacturing capacity, insurance coverage, and global access remain significant hurdles. However, with retatrutide demonstrating such profound efficacy in its initial late-stage outing, Eli Lilly has solidified its position at the vanguard of a medical revolution that is redefining the treatment of metabolic disease. The coming months will be critical as the company compiles its final data packages for the FDA, potentially setting the stage for a commercial launch that could once again rewrite the record books for pharmaceutical blockbusters.